GVHD (Graft-versus-host disease) can occur at any point in time following transplantation. The pathogenesis of GVHD include: Breakage of immune tolerance to self-antigens, down-regulated CD4+CD25+ regulatory T cells and the roles of B cells, and the antibodies they produce. A 22-year-old woman presented with maculopapular rash on whole body with fever. Patient has history of liver transplantation due to fulminant hepatic failure. After 1 month of high dose methylprednisolone treatment, there was a clinical improvement; however, one week later, leukopenia and creatinine elevation were seen, and worsening of skin lesion. Patient was treated with ruxolitinib and after a month of treatment, the lesions were mostly cleared and there was no manifestation of recurrence after more than 6months of follow-up. High-dose Corticosteroids and calcineurin inhibitors are the initial systemic therapy of choice for patients with moderate to severe chronic GVHD. But at present, second-line treatment is ill-defined and includes a number of agents. Overall, our findings suggest that Ruxolitinib played a fundamental role in the successful GVHD treatment of the patient.